What Кордиамин (Nikethamide) Treats: Main Uses and Benefits

The therapeutic application of Кордиамин (Nikethamide) is considered relevant for providing acute support in critical scenarios, offering supportive relief from symptoms related to significant physiological strain. The Anatomical Therapeutic Chemical (ATC) classification system designates the medication as a respiratory stimulant, defining its core therapeutic scope.

The medicine is commonly used to help manage symptoms associated with systemic imbalance, circulatory insufficiency, and compromised mental lucidity resulting from central nervous system (CNS) suppression. It is applied in clinical settings, such as to manage symptoms following anesthesia or drug overdose, or during episodes of acute shock.

“The goal is supportive relief, helping the patient maintain a sense of functional stability during an acute physiological crisis.”

The primary benefit generally supports symptoms related to systemic imbalance by assisting with respiration, which helps with functional stability and contributes to easing the overall symptom load associated with significant physiological strain.

---

Quick Fact: Relief for Diminished Respiratory Function This medication is relevant when supportive symptom management is appropriate for conditions presenting with symptoms related to noticeable physiological strain or diminished respiratory function.

Regulatory References

1. WHO Anatomical Therapeutic Chemical (ATC) classification system

The use of Кордиамин (Nikethamide) is strictly defined by regulatory eligibility criteria and subject to several absolute restrictions focused on preventing severe central nervous system (CNS) overstimulation.

Populations Not Eligible for Use (Contraindications)

Status	Population or Condition
Absolutely Prohibited	Epilepsy or any history of convulsive disorders or seizures.
Absolutely Prohibited	Known hypersensitivity to Nikethamide or its components.
Absolutely Prohibited	Pregnancy and the period of Lactation (breastfeeding).
Absolute Exclusion	The presence of hyperthermia (high fever) in children.

Eligible and Restricted Populations

Eligibility is established for the general adult population and, under specific medical guidance, for newborns experiencing specific acute conditions, such as asphyxia, provided no contraindications are present. For women who are breastfeeding, regulatory instructions mandate a condition: the issue of discontinuing breastfeeding must be officially resolved before the medicine can be administered. These rules establish clear population boundaries based on safety considerations.

Interactions with other medicines and products — Official Regulatory Information for Кордиамин (Nikethamide)

Category	Official Regulatory Statements
Medicinal product categories with documented interactions	Antiepileptic Agents, Narcotic Analgesics, Hypnotics, Antipsychotics, Anxiolytics, Psychostimulants, Antidepressants, MAO Inhibitors, General Anesthetics.
Specific interacting medicines (if explicitly listed)	Phenytoin, Aminazine, Reserpine.
Mechanistic basis of interactions	Pharmacodynamic interaction (CNS additive/counteractive effects), Physicochemical incompatibility.
Timing-based interaction rules	The injectable solution must not be mixed with other medicinal products due to physical incompatibility.

---

Classification	Official Regulatory Statements
Interaction severity classification	Reduction of efficacy (e.g., Anticonvulsants) and enhancement of stimulatory/pressor effects (e.g., MAO Inhibitors).
Regulatory basis	National Drug Labels and Official State Registers of Medicines.

---

Official Interaction Statements:

• The co-administration with antiepileptic agents (e.g., Phenytoin) is officially documented to reduce the efficacy of the anticonvulsant medicine.
• Use with narcotic analgesics, hypnotics, antipsychotics, or anxiolytics results in the reduction of their therapeutic effects.
• The pressor effect is documented to be enhanced by MAO Inhibitors and the overall stimulatory effects by other psychostimulants and antidepressants.
• The injectable solution is subject to the regulatory constraint that it must not be mixed with other medicinal products.
• Co-administration with Alcohol (Ethanol) is associated with the risk of exacerbated CNS stimulatory outcomes.

Connection to the overall interaction profile: Regulatory documents define the product's interaction structure primarily through pharmacodynamic conflict, requiring caution against combinations that either counteract CNS depressant drug efficacy or increase the risk of CNS overstimulation. This profile is further structured by physical incompatibility rules for the parenteral formulation, which mandates separation from other substances.

How Кордиамин Works: Mechanistic Domains

The mechanism of action for Nikethamide is based on its role as a non-selective stimulant acting on central respiratory and vasomotor centers and their peripheral feedback loops.

Direct Stimulation of Central Respiratory Control

Nikethamide achieves its primary action through the direct excitation of specialized neurons within the Medulla Oblongata of the brainstem. By augmenting the excitability of the Respiratory Centers, this mechanism initiates a cascading signal that increases the frequency and strength of neural output to the breathing muscles. The physiological consequence is a direct increase in the activity of the central ventilatory drive, resulting in an increase in the rate and depth of respiration (tidal volume).

Sensitization of Peripheral Ventilatory Feedback

The drug also affects the Peripheral Chemoreceptors (carotid and aortic bodies). Nikethamide acts to increase the responsiveness of these sensory structures to existing blood gas changes, specifically carbon dioxide ( CO2). This sensitization reinforces the central drive by supplying stronger reflexive signals to the brainstem, which contributes to the resulting increase in minute ventilation.

Non-Selective Neuronal Excitation

As a non-selective CNS excitatory modulator, the molecule's action extends beyond the respiratory pathways to include the adjacent Vasomotor Center. This stimulation produces secondary changes in autonomic tone, resulting in modulation of heart rate and peripheral vascular resistance.

How to Use Кордиамин

The usage of Кордиамин (Nikethamide) is strictly governed by protocols established in official regulatory documents, dictating its administration as a short-term, acute intervention. The medicine is primarily available and approved as a 25% Solution for Injection and is intended for immediate action, not chronic or prophylactic treatment.

---

Official Administration Guidelines

Usage Parameter	Regulatory Instruction
Route of Administration	Primarily Intravenous (IV), Intramuscular (IM), or Subcutaneous (SC) injection. Oral drops are authorized in some regions.
Adult Acute Dose	The typical single dose is 1.5 mL to 2 mL, with the 2 mL volume representing the maximum single dose allowed for acute administration.
Frequency Pattern	Intermittent, as-needed use. A single dose may be repeated every 1 to 3 hours during an acute episode, provided the total daily dose does not exceed the maximum of 10 mL.
IV Technique	The intravenous injection must be administered slowly to comply with proper use protocol. The solution must be confirmed clear before administration.
Pediatric Dosing	Specific, weight-adjusted dosing is mandated for children, with doses ranging from 0.1 mL to 0.75 mL depending on the specific official guidance and patient weight.

---

Context of Use

The required use protocols ensure that the medicine is administered rapidly via parenteral injection when needed, which necessitates a specialist supervision or hospital setting. The strict limitations on single and daily dosing define this medication's function as a time-dependent resource used solely for acute, limited episodes.

Summary of Clinical Evidence and Current Status

Кордиамин (known by its generic name Nikethamide) is a central nervous system and respiratory stimulant that was historically used to treat respiratory depression, particularly in cases of drug overdose or during anesthesia. The drug was initially developed in the early 20th century and marketed widely under the trade name Coramine.

Today, Nikethamide is generally not recommended for treating respiratory depression due to the narrow therapeutic window; the dose required for an effective respiratory stimulating effect is considered close to the dose that can cause toxic effects, such as convulsions.

Modern Clinical and Regulatory Standing

With the development of safer and more effective methods for respiratory support, such as mechanical ventilation and endotracheal intubation, Nikethamide’s role in critical care has significantly declined in many regions, including the United States and parts of Europe, where it is often considered to be of limited or no value for overdose treatment.

• Current Use: Despite its reduced use in emergency medicine, Nikethamide remains available in some countries, occasionally combined with glucose, and may be used as a short-acting stimulant to counteract drowsiness or fatigue in specific contexts. However, its continued use for respiratory depression in most modern clinical settings is discouraged.
• Safety Profile Note: Common adverse effects reported include restlessness, anxiety, high blood pressure (hypertension), and irritation at the injection site. The risk of seizures and cardiac arrhythmias remains a significant concern, especially at higher doses. It is contraindicated for individuals with conditions like epilepsy, severe hypertension, and cerebral edema.

Key Studies & References

1. Nikethamide – Knowledge and References (Overview of mechanism, toxicity, and historical use)

Common questions about Кордиамин (FAQ)

Q: Can people use Кордиамин for low blood pressure or fainting?

A: Official regulatory documents classify Кордиамин primarily as a specialized respiratory stimulant used for diminished breathing. However, the drug's known mechanism of action involves stimulating the Vasomotor Center, which has a role in regulating peripheral vascular resistance and autonomic tone. The approved primary purpose is defined in official product information as a specialized respiratory stimulant.

---

Q: How quickly does a person typically feel the effects of Кордиамин?

A: The drug is officially classified as a short-acting stimulant and is administered for acute intervention, consistent with a rapid onset. Studies examining the drug's behavior in the body indicate that the elimination half-life is approximately 30 minutes (0.5 hours).

---

Q: How long does the effect of Кордиамин usually last in the body?

A: Pharmacokinetic data indicates the drug has a relatively short presence in the body, with an elimination half-life of about 30 minutes. Regulatory documents describe a protocol that allows for repeating a dose every one to three hours during an acute episode, which is consistent with its short half-life.

---

Q: Are there specific differences between the injectable and liquid drop forms of Кордиамин?

A: Official regulatory information mainly details the 25% Solution for Injection, which is formulated for rapid, parenteral (injection) use in acute settings. While some regulatory bodies also authorize oral drops for use in certain regions, the specific dosage instructions and context of use for this liquid form can vary depending on the local product label.

---

Q: What are the most frequently reported side effects of Кордиамин in official documents?

A: According to the official product information, many of the drug’s documented adverse reactions are listed with a 'Frequency not defined' classification. This means official labels generally do not provide specific rates of occurrence (such as 'common' or 'rare') for most side effects. Therefore, official regulatory classifications do not permit a definitive ranking of which side effects are the most frequent.

---

Q: Can Кордиамин be used to help with shortness of breath?

A: The primary purpose, as described in official labeling, is for the drug to serve as a respiratory stimulant in cases of diminished or depressed breathing. However, when reviewing the drug's safety information, official lists of potential adverse reactions include dyspnoea, which is the medical term for shortness of breath.

---

Q: What is the difference between a 'respiratory analeptic' and other types of stimulants?

A: Regulatory classifications define this drug as a specialized Analeptic agent, which is a type of stimulant focused specifically on the respiratory system. It works primarily by directly exciting the respiratory centers in the brainstem to increase the rate and depth of breathing. The molecule is also documented as a non-selective Central Nervous System (CNS) excitatory modulator.

---

Q: Can Кордиамин cause fluctuations in body temperature?

A: Official regulatory documents list the presence of hyperthermia (a significantly high fever) as an absolute exclusion for use in children. This safety constraint is consistent with the drug’s central nervous system stimulatory actions and its potential effect on the body’s thermal regulation.

---

Q: What does the research say about using Кордиамин to counteract opioid effects?

A: Historically, the drug was used to address respiratory depression associated with drug overdose, including those involving narcotic analgesics. However, official interaction statements describe that co-administration is documented to reduce the therapeutic effects of narcotic analgesics. In modern clinical settings, the use of this drug for overdose treatment has declined due to the development of alternative respiratory support interventions.

How to Store and Dispose of Кордиамин

This section outlines the regulatory requirements for storing and disposing of Кордиамин (Nikethamide) as stated in official labeling documents.

Storage Requirement	Official Condition
Temperature	Store at a temperature no higher than 25 C.
Protection	Protect from light; keep in the original package.
Handling	Keep the product out of the reach of children.
Stability	Shelf-life is maintained until the expiration date when stored correctly.

Кордиамин must be kept away from light and stored at or below 25 C. To maintain stability and prevent misuse, always keep the product secured in its original container and out of the sight and reach of children. Do not dispose of the medication with household waste. All used or expired product must be discarded according to relevant local and national environmental and medical waste disposal regulations.